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Objective: The aim of this review was to examine aspirin utilization, cardiovascular risk 
  estimation, and clinical evidence for aspirin prophylaxis in Asian versus Western countries.
Methods: A literature search was performed using PubMed and the key terms “aspirin” and 
“Asia” or “Western”.
Results: Despite the growing burden of cardiovascular disease (CVD), aspirin is underutilized 
in high-risk patients in both Asian and Western countries. A number of risk estimation scores 
are available; however, validation is needed in countries such as Japan, India, and in South 
Asia. Underutilization of aspirin in Asia may be linked to an overestimation of bleeding risks. 
It is possible that a higher prevalence of Helicobacter pylori infection and genetic differences 
may make Asians more susceptible to gastrointestinal bleeding. Very low aspirin doses and 
even the wider use of gastroprotective agents may be the optimal approach to high-risk patients 
in Asia.
Conclusions: Based on the current evidence, aspirin should be used for CVD prevention when 
the risk:benefit ratio is favorable. A number of trials are underway, including the Diabetic 
Atherosclerosis Prevention by Cilostazol and Japanese Primary Prevention Project, which will 
provide key data on the benefits of aspirin in Asian patients at risk of CVD, and may improve 
aspirin utilization and risk estimation.
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Introduction
Cardiovascular disease (CVD) is a major cause of death worldwide. It is estimated 
that 58.1% of all deaths in Eastern Europe and Central Asia are due to CVD; the cor-
responding values in South Asia and East Asia and the Pacific are 25.2% and 30.6%, 
respectively. In high-income countries (mainly North America and Europe), 38.5% of 
all deaths are attributable to CVD.1 These percentages are likely to increase, given that 
the worldwide mortality rate from CVD (including stroke) is predicted to rise to 25 
million per year by 2020.2,3 The increase in CVD death rates will be most dramatic in 
low- to middle-income Asian countries, such as India and China. In China alone, the 
number of deaths from CVD is estimated to reach a staggering 13 million by 2020.4,5 
It is thought that the epidemiologic transition that is taking place in these countries 
could account for such changes. This transition may also result in a shift toward an 
aging population, which could further add to the burden of CVD, particularly in 
developing countries.1
Although the increasing prevalence of CVD is clearly a burden for many countries,1,2 
the economic implications of the disease are a particular problem for many low- to Vascular Health and Risk Management 2010:6 944
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middle-income Asian countries.6 It is estimated that 84 billion 
dollars of economic production will be lost due to CVD in 
low- to middle-income countries; however, an additional 2% 
reduction in annual death rates from CVD could save around 
8 million dollars and prevent 24 million premature deaths,7 
intensifying the need for effective preventive strategies.
Aspirin is one of the most effective antiplatelet agents 
for long-term prevention of vascular disease in individuals 
determined as having a high risk of CVD.8 The aim of this 
review is to examine aspirin utilization, CVD risk estimation, 
guideline recommendations, and clinical evidence for aspirin 
prophylaxis in Asian and Western countries.
Methods
A literature search was performed using PubMed and the 
search terms “aspirin; acetylsalicylic acid” and “Asia” or 
“European” or “Western” with the limits ‘clinical trial’, 
‘meta-analysis’, ‘practice guideline’ and ‘review’. The 
additional search terms “cardiovascular”, “epidemiology”, 
“utilization”, “safety”, “efficacy”, “risk factors”, “risk scores”, 
“primary prevention”, “secondary prevention”, and “non-
  responsiveness” were also applied. All retrieved publications 
were manually reviewed and the relevant ones were organized 
according to the subheadings used in this review.
Aspirin use in Asian  
and Western countries
Despite consistent recommendations from international 
guidelines,9−15 aspirin is underutilized in many high-risk 
patients in both Western and Asian populations.16–19 In a 
survey of 7363 physicians from Europe, Latin America, 
and Asia, aspirin was recommended by most physicians 
(85%) for patients following myocardial infarction (MI).20,21 
However, compliance was suboptimal; 45% of patients in 
Asia and 29% of patients in Europe were estimated to be 
noncompliant according to the treating physician. The main 
reasons for underutilization of aspirin were poor patient 
compliance and poor patient follow-up.20,21 A recent study 
of the Chinese Registry of Acute Coronary Events (CRACE) 
reported that only 34% of male patients and 39% of female 
patients with diagnosed acute coronary syndrome (ACS) used 
aspirin at study enrolment.22 Similarly, a study of Japanese 
patients in the Reduction of Atherothrombosis for Continued 
Health (REACH) registry revealed that aspirin use among 
Japanese patients with atherothrombotic disease was less 
common (54.7%) than the global REACH average (67.4%).23 
Overall, these findings indicate that underutilization is an 
issue in both Asian and Western populations.
CVD risk estimation in Asian  
and Western countries
Two of the key issues to be addressed by physicians are the 
risk:benefit threshold at which prophylactic agents should be 
used, and which risk factors should be used to determine such 
thresholds. Gaziano et al24 suggest that risk factors can be 
divided into those that are predictive, those that are treatment 
targets, and those that fall into both categories (Figure 1). 
Many of these risk factors are correlated, making it possible 
to determine a patient’s total CVD risk based on a few key 
risk factors.24 Nonlaboratory risk factors such as age, smok-
ing status, and body mass index (BMI) have been found to 
be as predictive as laboratory methods such as cholesterol 
measures in both men and women,25 and other blood tests, 
such as high-sensitivity C-reactive protein, hemoglobin A1c, 
fasting glucose, insulin, fibrinogen, adiponectin, triglycer-
ides, and plasminogen activator inhibitor-1, which may help 
simplify risk prediction.
A number of risk estimation scores, which are based on 
factors such as age, smoking, BMI, and cholesterol, are avail-
able for determining total cardiovascular risk. Many of these 
scores are also based on the concept that risk factors occur 
in clusters, and scoring these clusters represents a logical 
way to determine which patients are eligible for treatment 
and to determine the threshold for intervention.26 There are 
a number of scores available; the key ones are summarized 
by Gaziano et al.24 These include the National Cholesterol 
Education Program-Adult Treatment Panel III (NCEP-ATP 
III) risk score, which predicts the 10-year CVD risk, the Sys-
tematic Coronary Risk Evaluation (SCORE) project, which 
calculates the 10-year risk of CVD death; the Prospective 
Cardiovascular Munster (PROCAM) study, which determines 
the 10-year absolute risk of fatal MI, nonfatal MI or sud-
den cardiac death; and those produced by the New Zealand 
Guidelines Group that predict five-year total cardiovascular 
disease risk.27–30 The Reynolds Risk score, which incorporates 
high sensitivity C-reactive protein, predicts 10-year CVD risk 
in men and women.31,32 There are also a number of scores 
such as QRISK and ASSIGN, which are validated to specific 
populations such as the UK and Scotland.33
One of the most commonly used scores is the   Framingham 
model, which can be used to predict coronary heart disease 
(CHD) risk (defined as MI, CHD death, angina, and coro-
nary insufficiency)34 and CVD risk (defined as CHD plus 
stroke, congestive heart failure, and peripheral vascular 
disease).35 The Framingham model was originally devel-
oped in Western populations and has been validated in a 
Chinese population.36 However, there is also evidence to Vascular Health and Risk Management 2010:6 945
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suggest that the Framingham model overestimates CHD 
risk and underestimates CVD risk in China when compared 
with a prediction model specific to the Chinese population 
(Figure 2).37 This finding is based on a cohort of 9903 patients 
from the US-People’s Republic of China (US-PRC) cohort, 
where the actual incidence of ischemic CVD and CHD was 
determined over an 11-year follow-up period. The Chinese 
prediction model accounts for the higher prevalence of stroke 
in China,37 which could be the main reason for the differ-
ent results. However, the authors do not state whether the 
Framingham model was recalibrated to take into account the 
CVD definition (including stroke) that is described above. 
Nonmodifiable
factors:
Modifiable
factors:
Preventive
medications:
Predict risk Reduce risk
Age,
Gender,
FH
Diagnostic/
screening tests:
ETT, EBT,
ECHO,
CRP
Smoking,
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Figure 1 Risk factors can be divided into those that are predictive, those that are treatment targets, and those that fall into both categories.24 Copyright © 2007, Elsevier. 
Reproduced with permission from Gaziano JM, Manson JE, Ridker PM. Primary and secondary prevention of coronary heart disease. In: Libby P, Bonow RO, Mann DL, et al, edi-
tors. Libby: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders; 2007;1119–1148.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CRP, C-reactive protein; EBT, electron beam 
tomography; ECHO, echocardiography; ETT, exercise tolerance test; FH, family history; PCI, percutaneous coronary intervention.
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Figure 2 Comparison of Framingham model and Chinese prediction model on ischemic CVD and CHD incidence in a Chinese cohort.37 Copyright © 2006. Reproduced with per-
mission from Wu YF, Liu XQ, Li X, et al. Estimation of 10-year risk of fatal and non-fatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114(21):2217–2225.
Abbreviations: CHD, coronary heart disease; ICVD, ischemic cardiovascular disease.Vascular Health and Risk Management 2010:6 946
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The main differences between the Framingham model and 
the Chinese prediction model relate to age (Framingham 
captures an older cohort), cholesterol (the Chinese prediction 
model only captures total cholesterol), BMI (only included in 
the Chinese prediction model), and diastolic blood pressure 
(only in the Framingham model).
A number of studies have also shown that cardiovascular 
risks differ between European and Asian countries. The Inter-
national Collaborative Study of Cardiovascular Disease in 
Asia (InterASIA) survey found that risk levels were lower 
in China than in the US (Table 1).38 These authors used 
dyslipidemia, hypertension, diabetes, smoking, and weight 
to assess risk level; however, age was not used as part of the 
initial assessment. Comparison of Western and Asian data 
also reveals that different levels of risk are found within 
the two regions; based on data from a Japanese survey, a 
50-year-old male with no hypertension or diabetes in the US 
has a 3% risk of developing CVD in the subsequent five years, 
while a male with the same profile in Japan has a risk of only 
0.8%.39 The World Health Organization (WHO) determined 
the percentage of patients with a 10-year CVD risk 30%; 
they reported that 11.7% of the US population, 16.19% of the 
European population, and 11.44% of the Asia–Pacific popu-
lation were in this category (data are pooled percentages),26 
which indicates that risks were comparable between the US 
and Asia but were much higher in Europe.
In addition to validating risk estimation scores in Asian 
populations, there is also evidence to suggest that develop-
ing country-specific models or recalibrating and validating 
existing models such as the NCEP-ATP III, SCORE, or 
Framingham model could result in more accurate CVD risk 
estimates. Using a derivation cohort of 1.28 million and a 
validation cohort of 0.61 million patients from practices in 
the UK, cardiovascular risks were calculated using QRISK 
and Framingham, and were compared against actual events 
over a 10-year period.33 The Framingham model overpre-
dicted cardiovascular risk at 10 years by 35% and QRISK 
by 0.4%, which indicates that QRISK may be better suited 
to the UK population. It is possible that a similar trend may 
be observed in different Asian countries.
Risk profiles may also differ between different Asian 
countries, which is another reason for country-specific rather 
than regional guidelines. In one case-control study involving 
27,095 patients, the mean age for first MI was lower in South 
Asian countries compared with other countries, including 
other Asian countries (53 versus 58.8 years; P  0.001).40 
South Asians were found to have more risk factors, such as 
lipid abnormalities and diabetes at a younger age (60 years) 
compared with the other countries. The INTERHEART 
study, which enrolled 12,190 patients, also showed that South 
Asians had lower high-density lipoprotein (HDL) cholesterol 
compared with the rest of Asia.41 South Asians have also been 
shown to have a higher incidence of fatal CHD at a younger 
age compared with Chinese or European subjects.42–44 These 
findings indicate that age thresholds, HDL cholesterol and 
CHD risk levels may be different in South Asia compared 
with the rest of Asia, and these need to be incorporated into 
risk estimation scores. Differences in diet may also be another 
factor worthy of consideration. Other studies have shown that 
insulin resistance may be higher in American Indians and 
triglyceride levels may be higher in Japanese Americans 
compared with other American populations;45 if such factors 
are not addressed in risk estimation scores then it is possible 
that total risk will not be properly addressed.
In order to encourage the wider use of risk estimation 
scores in different countries, the WHO has produced a 
series of pocket guidelines for Africa, the US, the Eastern 
Mediterranean, Europe, South-East Asia, and the Western 
Pacific, which take these different risk profiles into account. 
However, the WHO does not state which evidence or score 
they used to assess the different risk profiles per region nor 
how they validated the score in each country. The WHO 
also acknowledges that there are limitations with these risk 
scores, such as which risk factors are most predictive of 
events and whether new risk factors (eg, waist-hip ratio) 
should be included. They add that there is strong evidence that 
reducing the level of these risk factors has beneficial effects, 
which is probably the main take-home message for general 
practitioners from both Asian and Western countries.
Guidelines in Asian versus  
Western countries
Disease management guidelines recommend the use of aspi-
rin for the prevention of first and recurrent CVD events in 
high-risk patients (usually defined as having a 10-year CHD 
Table 1 Prevalence of major cardiovascular risk factors* in rural 
and urban China and the US†
China % (SE) US % (SE)
Rural Urban
1 risk factor 79.9 (0.5) 83.1 (0.5) 93.1 (1.1)
2 risk factors 44.0 (0.7) 53.6 (0.7) 73.0 (1.8)
3 risk factors 15.4 (0.5) 24.5 (0.6) 35.9 (1.8)
Notes: *Risk factors were dyslipidemia, hypertension, diabetes, current smoking, and 
  overweight. †Adapted from Gu et al.38
Abbreviation: SE, standard error.Vascular Health and Risk Management 2010:6 947
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risk of 20%−30% according to the Framingham model). 
Table 2 summarizes recommendations from the main 
European and US guidelines.9−15,46 In addition, the Chinese 
guidelines recommend prophylaxis in patients with a 10-year 
CHD 10% as predicted by the Framingham model.47 The 
recently published US Preventive Services Task Force (USP-
STF) guidelines recommend aspirin prophylaxis when the 
number of CVD events prevented (MI in men and stroke in 
women) outweighs any potential side effects such as gas-
trointestinal (GI) bleeds (Figure 3).46 In order to determine 
the threshold for treatment, the guidelines recommend a 
CHD risk estimation tool for men and a stroke estimation 
tool for women; however, the guidelines do not discuss how 
these scores have been validated in both Western and Asian 
populations.
Yoon et al48 found that application of the NCEP-ATP III 
guidelines, which were mainly developed from Caucasian 
patients, to data from the Korea Acute Myocardial Infarction 
Registry (KAMIR) resulted in undertreatment. Around 69% 
of patients with an acute MI did not qualify for drug therapy 
when they were stratified according to the risk factors pres-
ent and the 10-year CHD risk. Again, this indicates that risk 
estimation scores specific to Asian populations are warranted, 
particularly to determine the risk:benefit threshold of aspirin 
use in each ethnic group. Important differences between 
populations should be considered when   extrapolating 
guidelines developed in one country for use in another.39 
Underutilization of prophylactic agents is a key issue in Asian 
countries, which may, in part, be due to an overestimation 
of bleeding risks.49 It is possible that a lack of validated risk 
estimation models and guidelines in these countries could 
be a contributing factor to poor utilization rates.
Clinical efficacy of aspirin  
in CVD prevention
First event reduction
Much of the evidence supporting the role of aspirin in the 
prevention of first CVD events comes from several large-
scale trials, which are summarized in Table 3.50−56
A meta-analysis of five of these key trials (Physicians’ 
Health Study [PHS], British Male Doctors’ Trial [BDT], 
Hypertension Optimal Trial [HOT], Thrombosis Prevention 
Project [TPP], and the Primary Prevention Project [PPP]) 
reported a 32% reduction in the risk of a first MI and a 15% 
reduction in any important vascular events (combined endpoint 
of vascular death, nonfatal MI, or nonfatal stroke) associated 
with aspirin use.57 A further meta-analysis that also incorpo-
Table 2 Summary of recommendations for aspirin use from a selection of recent European and US guidelines
Association Recommendations for aspirin therapy
European Society of Cardiology10 • Aspirin recommended for all patients with NSTE-ACS without contraindications
•   Aspirin 160–325 mg/day is recommended as the initial loading dose; and aspirin 75–100 mg/day 
is recommended for long-term therapy
European Society of Cardiology/ 
European Society of Hypertension9
• Aspirin therapy is favorable if 10-year cardiovascular risk is 15%–20%
•   Aspirin 75–100 mg/day is recommended for hypertensive patients with previous history of CVD 
or aged 50 years with a moderate increase in serum creatinine or risk factors
European Society of Cardiology/ 
European Association for the Study of Diabetes14
• Aspirin 75–250 mg/day is recommended for first and recurrent stroke prevention
American College of Cardiology/ 
American Heart Association11
•   Aspirin 75–162 mg/day is recommended in all UA/STEMI patients with a 10-year CHD risk 
10% plus 2 risk factors
• Aspirin 162–325 mg/day should be used for patients with stents
American Heart Association12 • Aspirin 75–325 mg/day is recommended for high-risk women (a 10-year risk of CHD 20%)
•   Aspirin 81 mg/day or 100 mg qod is recommended if benefits outweigh risks of hemorrhagic 
stroke or bleeding in women
American Heart Association/ 
American Diabetes Association13
•   Aspirin 75–162 mg/day is recommended for CHD prevention in diabetes patients with 
increased cardiovascular risk
American Heart Association/ 
American Stroke Association15
•   Aspirin is recommended for cardiovascular (including but not specific to stroke) prophylaxis 
among persons whose risk is sufficiently high for the benefits to outweigh the risks (10-year 
risk of cardiovascular events of 6–10%)
US Preventive Services Task Force46  •   Aspirin therapy is recommended for MI prevention in men aged 45–79 years and stroke 
  prevention in women aged 55–79 years
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome;   
UA/STEMI, unstable angina/non-ST-elevation myocardial infarction; qod, once daily.Vascular Health and Risk Management 2010:6 948
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rated data from the Women’s Health Study (WHS)53 showed 
that aspirin significantly reduces the combined risk of CHD, 
nonfatal MI, and cardiovascular events.58 The most recent 
meta-analysis performed by the Antithrombotic Trialists’ 
Collaboration (ATTC), which also included all six primary 
prevention trials (n   =   95,000), showed that aspirin was associ-
ated with a 12% reduction in serious vascular events.59
The Japanese Primary prevention of atherosclerosis with 
Aspirin for Diabetes (JPAD) trial,56 which is not included in 
the meta-analyses to date, has provided important data on the 
role of low-dose aspirin (80–100 mg/day) in the prevention 
of first cardiovascular events in 2539 Japanese subjects with 
Type 2 diabetes. After a follow-up period of around four 
years, aspirin therapy was associated with a trend toward a 
20% reduction in atherosclerotic events, including fatal or 
nonfatal CHD, fatal or nonfatal stroke, transient ischemic 
attack, and peripheral arterial disease. JPAD also showed a 
significant reduction in vascular death in patients with diabetes 
who received low-dose aspirin. In a subgroup analysis, aspirin 
was associated with a significant reduction in atherosclerotic 
events in patients aged 65 years. Since the overall event rates 
were lower than expected, it is possible that a greater benefit 
Men
age 45–79 years
Women
age 55–79 years
Women Men
Age Age 10-year CHD risk 10-year stroke risk
Encourage aspirin use
when potential CVD benefit
(MIs prevented)
outweighs potential harm
of GI hemorrhage
Encourage aspirin use
when potential CVD benefit
(strokes prevented)
outweighs potential harm
of GI hemorrhage
Risk level at which CVD
events prevented (benefit)
exceeds GI harms
45–59 years 55–59 years
60–69 years 60–69 years
70–79 years 70–79 years
≥4% ≥3%
≥8% ≥9%
≥12% ≥11%
Figure 3 Summary of recommendations for low-dose aspirin therapy from the US Preventive Services Task Force.46
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; GI, gastrointestinal; MI, myocardial infarction.
Table 3 An overview of aspirin trials for the prevention of primary events
  PHS50 BDT51 HOT52 WHS53 PPP54 TPT55 JPAD56
Main country US UK 26 countries US Italy UK Japan
Aspirin dose 325 mg qod 500 mg/day 75 mg/day 100 mg qod 100 mg/day 75 mg/day 81–100 mg/day
Patients (n) 22,071 5139 18,790 39,876 4495 5499 2539
Reduction in 
CV events (%)
44 (MI) 10 (mortality) 15 (major CV 
events)
17 (stroke) 23 (composite  
CV endpoint)
20 (IHD) 20 
32 (65 years)
Conclusions 
 
Aspirin reduces  
MI 
No significant  
difference between  
aspirin or placebo
Aspirin reduces 
major CV events 
Aspirin reduces  
stroke (no effect  
on MI or CV death)
Terminated early 
 
Aspirin reduces  
nonfatal IHD 
Aspirin beneficial 
in older patients 
Abbreviations: PHS, Physicians’ Health Study; BDT, British Male Doctors’ Trial; HOT, Hypertension Optimal Trial; WHS, Women’s Health Study; PPP, Primary Prevention 
Project; TPT, Thrombosis Prevention Trial; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; CV, cardiovascular; IHD, ischemic heart disease; 
qod, once daily.Vascular Health and Risk Management 2010:6 949
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of aspirin therapy could have been observed in a larger trial 
population with a longer duration of follow-up.60
The JPAD trial also demonstrates the safety of low-dose 
aspirin in a Japanese population, with the risk of hemorrhagic 
stroke, which is the most serious potential complication of aspi-
rin therapy, being no greater among patients receiving aspirin 
than in the control group (six versus seven, respectively).56 
This observation is of particular clinical importance given that 
hemorrhagic stroke is more common in Japanese than Western 
populations, and it demonstrates the tolerability of low-dose 
aspirin therapy in this high-risk Japanese population.60
Overall, the JPAD study confirms the role of aspirin in the 
prevention of first events in an Asian population.56 However, 
to date, there are no trials that have directly compared the 
efficacy of aspirin in the prevention of first events according 
to ethnicity.
Recurrent event reduction
The ATTC clearly demonstrated the benefits of low-dose 
aspirin (75–150 mg/day) for the prevention of recurrent 
events in trials involving 17,000 patients.8 In patients with 
a prior history of vascular disease, antiplatelet therapy, of 
which aspirin was the most widely studied, was associated 
with notable reductions of approximately 25% in the risk of a 
combined outcome of any serious vascular event, 32% in the 
risk of nonfatal MI, 25% in the risk of nonfatal stroke, and 
15% in the risk of vascular mortality. The most recent meta-
analysis from the same group,59 which analyzed data from 
16 secondary prevention trials in 17,000 patients, showed 
that aspirin was associated with a greater reduction in serious 
adverse events compared with placebo (6.7% versus 8.2% 
per year, P  0.0001).
Data from Asia are similarly conclusive, in that use of 
aspirin 50 mg/day in Chinese patients (n = 216) has been 
associated with a reduction of 65% in the incidence of sec-
ondary reinfarction compared with patients who received 
no antiplatelet therapy.61 It is interesting to note that in this 
study, the reduction in incidence of secondary reinfarction 
was observed in males, but no significant trend was observed 
in females. In addition, the Japanese Antiplatelets Myocar-
dial Infarction Study (JAMIS) demonstrated that long-term 
low-dose aspirin (81 mg/day) prevented recurrent acute 
MI in postinfarction patients after thrombolysis or coro-
nary angioplasty.62 Finally, the Chinese Acute Stroke Trial 
(CAST, n = 21,106) confirmed the benefits of aspirin treat-
ment (160 mg/day) started within 48 hours of a suspected 
acute ischemic stroke.63 In patients treated with aspirin for 
up to four weeks, there was a significant reduction in the 
combined in-hospital endpoint of death or nonfatal stroke 
compared with untreated patients (12% proportional risk 
reduction, P = 0.03).
In summary, the findings from these trials indicate that 
aspirin is effective in the prevention of recurrent events in 
both European and Asian cohorts. There are no studies that 
have directly compared the effect of aspirin on the prevention 
of recurrent events according to race; however, the findings 
from the ATTC indicate that recurrent MI was reduced by 
32% compared with 65% in the Chinese study.8,59 Although 
it is difficult to make comparisons given the huge difference 
in patient numbers, and differences related to other factors 
such as treatment duration, definition of endpoints, time since 
first MI, age, sex and other characteristics, it is possible that 
ethnicity may also be a contributory factor.
Combination therapy in high-risk patients
Multidrug regimens including aspirin are often recommended 
as a comprehensive CVD preventive strategy.14 Furthermore, 
combined therapy with more than one antiplatelet agent may 
offer improved cardiovascular protection owing to the additive 
effects of activating complementary antiplatelet pathways. 
However, combining aspirin with another antiplatelet agent 
should take into account benefits gained over safety issues. 
For example, the Clopidogrel for High Atherothrombotic 
Risk and Ischemic Stabilization, Management, and Avoid-
ance (CHARISMA) and Management of Atherothrombosis 
with Clopidogrel in High-risk Patients (MATCH) trials 
showed that the combination of clopidogrel plus aspirin was 
comparable with aspirin alone in high-risk populations, but 
the risk of bleeding was higher with combination therapy 
(Table 4).64−71
A recent meta-analysis of five trials has also demon-
strated that aspirin plus pravastatin was more effective than 
either agent alone in the prevention of recurrent events, 
including ischemic stroke.72 The Aspirin and Simvastatin 
Combination for Cardiovascular Events Prevention Trial 
in Diabetes (ACCEPT-D) is currently investigating the 
effects of adding low-dose aspirin 100 mg/day to existing 
simvastatin therapy on the prevention of cardiovascular 
events in 5170 patients with Type 1 and Type 2 diabetes, an 
area in which data are surprisingly scarce.73 This study will 
provide important new information on the role of aspirin 
in diabetes when used in addition to other CVD prevention 
strategies. The ongoing A Study of Cardiovascular Events 
iN Diabetes (ASCEND) trial, which is evaluating the effect 
of aspirin with or without omega-3 fatty acids on CVD 
events in patients with diabetes over a five-year follow-up Vascular Health and Risk Management 2010:6 950
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period, will also provide additional information on aspirin 
in high-risk patients (Table 5).74
In addition, the triple combination of aspirin, clopidogrel, 
and enoxaparin is associated with a reduction in mortality 
and reinfarctions compared with standard therapy of unfrac-
tionated heparin in patients with ACS.75 Multiple regimens 
involving aspirin have been shown to be effective on a global 
scale. A research group recently estimated that a preventive 
regimen for high-risk patients based on aspirin, a statin, and 
two antihypertensives could help avert 17.9 million CVD 
deaths over 10 years (estimates based on 23 low- to middle-
income countries).76
Aspirin safety
The most common side effect associated with aspirin is bleed-
ing, which is related to its mechanism of action and the dose 
prescribed.77 The risk of GI hemorrhage with long-term use 
of aspirin was assessed in a meta-analysis of 24 randomized 
controlled trials involving almost 66,000 participants taking 
aspirin or no aspirin over a one-year treatment period.78 This 
analysis showed that GI hemorrhage was slightly higher in 
patients taking aspirin compared with no aspirin/placebo 
(2.47% versus 1.42%, respectively; OR: 1.68; 95% CI: 
1.51–1.88). The risk of GI hemorrhage was reduced when 
lower aspirin doses (163 mg/day) were used (2.30% versus 
1.45% (OR: 1.59; 95% CI: 1.40–1.81).
The impact of aspirin on hemorrhagic stroke has been 
addressed in another meta-analysis of 16 trials involving 
more than 55,000 participants.79 The mean dose of aspirin was 
273 mg/day and the mean dura  tion of treatment was 37 months. 
There was an increased absolute risk of 12 events (95% CI: 
5–20) per 10,000 persons over approximately three years, or 
about 0.4 excess events per 1000 users annually (P  0.001) 
associated with aspirin use. However, in this analysis, aspirin 
use was also associated with an absolute risk reduction in MI 
of 137 events per 10,000 persons (P  0.001) and an abso-
lute risk reduction in ischemic stroke of 39 events per 10,000 
persons (P  0.001). Overall, there was a clear benefit in the 
popula  tion at risk. In another meta-analysis involving almost 
57,000 subjects from 16 trials, there was no difference between 
aspirin and placebo in the risk of noncardiovascular death (RR: 
0.92; 95% CI: 0.81–1.04).80 It may be useful to re-examine 
the patients enrolled in these three key safety meta-analyses 
to determine how many were from Asian communities and to 
provide the risk factors for these patients alone.
In addition to the risks described above, the likelihood 
of adverse effects associated with aspirin also depends on 
the patient’s inherent risk level, so risk assessments should 
take into account any underlying conditions that predispose 
the patient to bleeding, such as hemophilia, uremia, or 
previous peptic ulcer.81 Again, it is important to note that 
different populations may have different inherent risks that 
will affect the patient’s threshold for prophylaxis. Physi-
cian concerns about safety issues could also have an impact 
on utilization of prophylactic agents. A recent Taiwanese 
study in patients with atrial fibrillation (n = 39,541) showed 
Table 5 Ongoing studies with aspirin
Trial name Country Cardiovascular risk  
factors in patients
Intervention
Diabetic Atherosclerosis Prevention  
by Cilostazol (DAPC) study
Japan, China, Philippines,  
and Korea
Diabetic atherosclerosis Cilostazol and  
aspirin
Japanese Primary Prevention  
Project with Aspirin (JPPP)
Japan At least one of: hypertension,  
hyperlipidemia, diabetes
Enteric-coated  
aspirin 100 mg
Low Dose Aspirin and Statins 
 for Primary Prevention of  
Atherosclerosis and Arterial  
Thromboembolism in Systemic  
Lupus Erythematosus (SLE)
Hong Kong Atherosclerosis,  
thromboembolism, SLE
Aspirin 80 mg,  
rosuvastatin 10 mg
Aspirin Dose and Atherosclerosis  
in Patients with Metabolic  
Syndrome (PAD)
US Metabolic syndrome Aspirin 81, 162,  
325, 650, or 1300 mg
A Study to Assess the Efficacy  
and Safety of 100 mg Acetylsalicylic  
Acid in Patients at Moderate Risk  
of Cardiovascular Disease (ARRIVE)
US, Italy, Puerto Rico At least two of: hypertension,  
hypercholesterolemia, diabetes,  
smoker, family history of early  
coronary heart disease
Enteric-coated  
aspirin 100 mg
ASCEND: A Study of Cardiovascular  
Events in Diabetes
UK Diabetes mellitus Aspirin,  
omega-3-acid supplementsVascular Health and Risk Management 2010:6 952
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that only 24.7% of the population received antithrombotic 
therapy. The main reason for low prescription rates was 
concern over bleeding risks.49 Overestimation of bleeding 
risk in Asian countries is an issue that needs to be addressed 
in guidelines with risk:benefit ratios that are tailored to 
these countries.
However, to date, there are no direct safety comparisons 
of aspirin in European versus Asian cohorts. This is a key 
area where further research is warranted because risk fac-
tors for GI ulceration may vary between the two regions; for 
example, Helicobacter pylori may be higher in Asian than 
European populations.82 Although the industrialization of 
Asian countries could erode this difference, it is possible that 
some Asian patients may be more susceptible to GI ulceration 
and may need lower doses of aspirin or concomitant use of 
gastroprotective agents. There is also evidence to suggest 
that the pattern of H. pylori infection may differ between 
Korean and Japanese patients compared with Americans.83 
The incidence of GI bleeding may also be affected by genetic 
differences related to cytochrome polymorphisms, which is 
another reason why comparative studies are needed. These 
factors may be a reason why aspirin is underutilised in Asian 
countries.49,21
Minimizing adverse events  
by low-dose aspirin
The risk of GI bleeding appears to be linked to aspirin dose 
and can be minimized by using a low-dose strategy; for 
example, use of aspirin 75 mg/day is estimated to reduce 
the risk of GI bleeding by 40% compared with 300 mg/day, 
and by 30% compared with 150 mg/day.78 Improved for-
mulations, such as enteric-coated aspirin, can also reduce 
the risk of GI bleeding.84 The antithrombotic efficacy of 
aspirin does not appear to be dose-dependent. Therefore, 
physicians should be encouraged to prescribe the lowest 
dose possible to ensure protection from cardiovascular 
events. Many guidelines support the use of low doses for 
primary prevention (as summarized in Table 2); however, in 
practice, prescription of higher doses is common. In a sys-
tematic review of published clinical trials, aspirin at doses 
as high as 1300 mg/day are approved for use; however, 
much lower doses (75–81 mg/day) have been shown to be 
as effective as higher doses with a lower risk of dose-related 
side effects such as GI bleeding.85 Another survey of 7363 
physicians showed that there were significant differences 
in the prescribing patterns between European and Asian 
countries.20,21 In Europe, 82% of physicians prescribed 
aspirin 100 mg/day for post-MI patients compared with 
63% in Asia (P  0.00001). There was a tendency for Asian 
countries to prescribe a wider range of aspirin doses.
Variable response to aspirin
Variations in individual responses to aspirin have been 
observed in clinical practice, which has led to the concept 
that certain individuals are resistant to some of its effects.86 
There is currently no universally accepted definition of “vari-
able response”, although it has been described as the failure 
of aspirin therapy to produce expected biologic effects, such 
as the inhibition of platelet aggregation, inhibition of throm-
boxane biosynthesis, or the failure to prevent atherosclerotic 
thrombosis in some patients. No diagnostic test of platelet 
function is currently recommended to assess the effects of 
aspirin in individual patients. Furthermore, incidence rates 
vary widely among studies, from 0.4% to 83%,87−90 which 
may reflect methodological differences in quantifying 
resistance rather than true resistance. Thus current opinion 
suggests that rather than being a medical phenomenon, 
variable response is actually the combined result of patient 
noncompliance when taking low-dose aspirin, possible 
drug-drug interactions, and lack of appropriate methods of 
cyclooxygenase-1 measurement.91
The future for aspirin in Asia
The large and growing number of deaths attributable to 
CVD clearly suggests a need for prevention, and more 
studies are warranted in Asian communities together with 
greater exploration of risk estimation scores and tailored 
guidelines. A number of studies are currently ongoing that 
should hopefully address some of the data needs (Table 5). 
The Japanese Primary Prevention Project (JPPP) is cur-
rently underway to evaluate the balance of risks and benefits 
of low-dose, enteric-coated aspirin in elderly Japanese 
patients (60–85 years) with one or more cardiovascular 
risk factors (hypertension, hyperlipidemia, and/or diabe-
tes). The study is designed to recruit 10,000 subjects who 
will be randomized to receive either aspirin 100 mg/day 
or placebo. A composite of nonfatal MI and/or stroke and 
cardiovascular death will be evaluated in the trial, and 
results are expected in 2010.92 In addition, the Diabetic 
Atherosclerosis Prevention by Cilostazol (DAPC) study, 
a collaboration between researchers from Japan, China, 
Philippines, and Korea, is investigating the efficacy of 
aspirin and cilostazol in the prevention and treatment 
of diabetic atherosclerosis in Asian patients (n = 408). 
The intima media thickness of the carotid artery will be 
assessed as the primary endpoint, with secondary endpoints Vascular Health and Risk Management 2010:6 953
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including incidence of cardiovascular events and all-cause 
mortality.93
Further studies are also needed to identify the true 
prevalence of aspirin-associated adverse events in Asian 
populations, and to determine the risk:benefit ratio accord-
ing to underlying CVD risk levels. In CAST, despite a trend 
toward more hemorrhagic strokes in patients treated with 
aspirin compared with placebo (P  0.1), the increased risk 
of adverse events did not influence the conclusion that the 
benefits of aspirin treatment for hospitalized stroke patients 
far outweighed the risks.63 Therefore, additional evidence is 
needed from specific populations at defined risks that can 
form the basis for relevant local guidelines. There is also 
a growing trend toward using aspirin in combination with 
other agents, including herbs such as ginkgo biloba, in Asian 
countries.94 Studies are needed to assess the possible benefits 
of such an approach.
Summary
Based on the current evidence and the recommendations from 
US and European guidelines, aspirin should be used for CVD 
prevention for all clinical conditions in which its risk: benefit 
ratio is favorable. Long-term, low-dose aspirin therapy is 
currently recommended for the prevention of severe vas-
cular events in moderate- and high-risk patients (including 
diabetics) and those with a history of vascular events. These 
guidelines should be followed to ensure optimal   prevention 
of cardiovascular events, with the knowledge that risk 
  estimation scores may need to be validated in a wider range 
of Asian countries in order to identify more accurate risk:
benefit thresholds. A number of trials are already underway, 
including the DAPC and JPPP in Asia, which will provide 
key data on the benefits of aspirin in Asian patients at risk of 
CVD. The recommendations and concerns regarding aspirin 
use are summarized in Table 6.
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